Related Experiment Video

Updated: Aug 8, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy

Mark J Smyth1, Yoshihiro Hayakawa, Erika Cretney

  • 1Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center, A'Beckett Street, Victoria 8006, Australia. mark.smyth@petermac.org

Journal of Immunology (Baltimore, Md. : 1950)
|May 4, 2006
PubMed

Insights

Combining antibody therapy targeting DR5 to induce tumor cell apoptosis with interleukin-21 (IL-21) suppressed tumor growth and metastases. This immunotherapy strategy also enhanced anti-tumor T cell activity and memory responses.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Tumor cell apoptosis is a key mechanism in cancer treatment.
  • Tumor-specific T cells are crucial for effective anti-tumor immunotherapies.

Purpose of the Study:

  • To investigate the synergistic effects of combining agonistic anti-Death Receptor 5 (DR5) monoclonal antibodies (mAbs) with interleukin-21 (IL-21) for cancer immunotherapy.
  • To evaluate the impact of this combination on tumor growth, metastasis, and T cell responses.

Main Methods:

  • Treatment of tumor-bearing models with agonistic anti-DR5 mAb.
  • Delayed administration of IL-21 following anti-DR5 mAb treatment.
  • Assessment of tumor growth, metastasis, and cytotoxic T lymphocyte (CTL) activity in various tumor models.

Main Results:

  • The combination therapy significantly suppressed tumor growth and pre-established metastases in DR5-sensitive tumor models.
  • Synergistic anti-tumor effects were observed with the combined approach.
  • IL-21 treatment enhanced tumor-specific CTL activity and promoted long-term memory responses.

Conclusions:

  • Combining DR5-mediated apoptosis induction with IL-21 is a promising strategy for cancer immunotherapy.
  • This combination enhances T cell-mediated anti-tumor immunity and memory.
  • The findings suggest a rational approach for developing novel cancer therapies.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...